These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 25146848)

  • 21. Induced Pluripotent Stem Cells and Organoids in Advancing Neuropathology Research and Therapies.
    Pazzin DB; Previato TTR; Budelon Gonçalves JI; Zanirati G; Xavier FAC; da Costa JC; Marinowic DR
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia.
    Albert K; Niskanen J; Kälvälä S; Lehtonen Š
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases.
    Gao A; Peng Y; Deng Y; Qing H
    Neuroscience; 2013 Jan; 228():47-59. PubMed ID: 23069758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling.
    Beghini DG; Kasai-Brunswick TH; Henriques-Pons A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling.
    Grekhnev DA; Kaznacheyeva EV; Vigont VA
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery.
    Chen SD; Li HQ; Cui M; Dong Q; Yu JT
    Expert Opin Drug Discov; 2020 Sep; 15(9):1081-1094. PubMed ID: 32425128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform.
    Garcia-Leon JA; Vitorica J; Gutierrez A
    Future Med Chem; 2019 Jun; 11(11):1305-1322. PubMed ID: 31161803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery.
    Qian L; Tcw J
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Soluble and Insoluble Protein Species in Patient-Derived iPSCs.
    Santarriaga S; Luecke I; Ebert AD
    Methods Mol Biol; 2022; 2429():73-84. PubMed ID: 35507156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery.
    Jang J; Yoo JE; Lee JA; Lee DR; Kim JY; Huh YJ; Kim DS; Park CY; Hwang DY; Kim HS; Kang HC; Kim DW
    Exp Mol Med; 2012 Mar; 44(3):202-13. PubMed ID: 22179105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progress in induced pluripotent stem cell research for age-related neurodegenerative diseases].
    Ito D; Yagi T; Suzuki N
    Brain Nerve; 2013 Mar; 65(3):283-8. PubMed ID: 23475520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neural stem cell-based treatment for neurodegenerative diseases.
    Kim SU; Lee HJ; Kim YB
    Neuropathology; 2013 Oct; 33(5):491-504. PubMed ID: 23384285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases.
    Trudler D; Ghatak S; Lipton SA
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induced pluripotent stem cells for modeling of pediatric neurological disorders.
    Jang J; Quan Z; Yum YJ; Song HS; Paek S; Kang HC
    Biotechnol J; 2014 Jul; 9(7):871-81. PubMed ID: 24838856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy.
    Tan CC; Yu JT; Tan MS; Jiang T; Zhu XC; Tan L
    Neurobiol Aging; 2014 May; 35(5):941-57. PubMed ID: 24360503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human-induced pluripotent stem cells: potential for neurodegenerative diseases.
    Ross CA; Akimov SS
    Hum Mol Genet; 2014 Sep; 23(R1):R17-26. PubMed ID: 24824217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells.
    Korecka JA; Levy S; Isacson O
    Mol Cell Neurosci; 2016 Jun; 73():3-12. PubMed ID: 26691153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induced pluripotent stem cells for neural drug discovery.
    Farkhondeh A; Li R; Gorshkov K; Chen KG; Might M; Rodems S; Lo DC; Zheng W
    Drug Discov Today; 2019 Apr; 24(4):992-999. PubMed ID: 30664937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of treating neurodegenerative disease with induced pluripotent stem cells.
    Pen AE; Jensen UB
    Acta Neurol Scand; 2017 Jan; 135(1):57-72. PubMed ID: 26748435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.